Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
188Re-N-DEDC lipiodol
- Development stage
- Preclinical
- Lead developer
- Bhabha Atomic Research Centre
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intra-arterial
01
Overview
**188Re-N-DEDC lipiodol** is an investigational therapeutic radiopharmaceutical for trans-arterial radionuclide therapy of unresectable hepatocellular carcinoma, including disease associated with portal vein thrombosis. It consists of the lipophilic beta-emitting rhenium-188 nitrido bis(diethyldithiocarbamate) complex, [188ReN(DEDC)2], extracted into Lipiodol, an iodized oil vehicle that preferentially localizes in hepatic tumor lesions after hepatic-artery administration. Local retention enables beta radiation delivery to tumor tissue and consequent radiation-induced cellular and DNA damage. Freeze-dried preparation kits were developed at Bhabha Atomic Research Centre for on-site labeling from a tungsten-188/rhenium-188 generator. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10202571/))
- Other names
- 188Re-N-DEDC Lipiodol188ReN-DEDC/lipiodol[188ReN(DEDC)2]/lipiodolrhenium-188-N-(DEDC)2/lipiodol
02
Targets
DNA
Beyond the preview
Go deeper on 188Re-N-DEDC lipiodol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 188Re-N-DEDC lipiodol.